Skip to main content

SynapDx Raises $15.4M

NEW YORK (GenomeWeb News) – Autism diagnostics firm SynapDx today said that it raised $15.4 million.

Google Ventures led the round with Foundation Medical Partners also a new investor. Founding investors North Bridge Venture Partners and General Catalyst Partners also participated in the round.

The funding will be used to support Lexington, Mass.-based SynapDx as it develops a blood-based diagnostic test for autism spectrum disorder. The test is designed to help clinicians identify children with autism earlier than can be currently diagnosed.

In conjunction with the financing, Google's Andrew Conrad was appointed to SynapDx's board. Conrad was the chief scientific officer of Laboratory Corporation of America and co-founder of its National Genetics Institute.

In February, LabCorp made a $2 million investment into SynapDx. SynapDx raised $6 million in a Series A1 financing round in December.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.